MiniMed completes separation from Medtronic

• MiniMed completed its separation from Medtronic, marking its first day trading as a fully independent company.
• Medtronic exchanged shares and completely exited its equity stake, with MiniMed shares trading unchanged at $22.50.
• The company stated the oversubscribed exchange offer marks a key strategic milestone for its diabetes business.

MiniMed (NASDAQ:MMED) completed its separation from Medtronic (NYSE:MDT) today, marking its first official day as an independent company.

Medtronic accepted 55,032,401 ordinary shares in exchange for 252,813,348 MiniMed common shares to complete the corporate split.
The transaction fully concluded Medtronic's ownership, and the former parent company no longer holds an equity stake in MiniMed.
The final exchange offer was 5.4 times subscribed by existing institutional and retail investors during the transaction period.

The company expects to focus exclusively on diabetes management technologies.

The separation allows MiniMed to allocate capital directly toward its specialized medical device research and development priorities

The independent business will continue operating its core insulin pump and continuous glucose monitoring technology platforms worldwide.